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The recent advancements in unraveling novel mechanisms that control the induction, (trans)differentiation, pro-
liferation, and thermogenic activity and capacity of brown adipose tissue (BAT), together with the application of
imaging techniques for human BAT visualization, have generated optimism that these advances will provide novel
strategies for targeting BAT thermogenesis, leading to efficacious and safe obesity therapies. This paper first provides
an overview of landmark events of the past few decades that have been driving the search for pharmaceutical and
nutraceutical compounds that would increase BAT thermogenesis for obesity management. It then addresses issues
about what could be expected from an ideal thermogenic antiobesity approach, in particular to what extent daily
energy expenditure will need to increase in order to achieve long-term weight loss currently achievable only through
bariatric surgery, and whether the human body will have enough thermogenic capacity to reach this target weight
loss by future therapies focused on BAT.
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Introduction
With the latest projections about the global burden
of obesity indicating that more than one billion peo-
ple will be obese by 2030 and twice that number will
be overweight,1 the global obesity epidemic, which
is the driving force behind an alarming explosion of
type 2 diabetes and cardiovascular diseases, is turn-
ing into a health crisis worldwide. This grim picture
is further compounded by the fact that the corner-
stone method for managing obesity (i.e., dieting)
has proven to be largely ineffective since few peo-
ple have the willpower to adhere to the hardships
of a dietary regime for a long period of time. The
result is generally a transient phase of weight loss,
a return on the trajectory toward obesity within a
few years,2 followed by repeated dieting and weight
cycling, which furthers the risks for cardiometabolic
diseases.3,4 Although in theory, an increase in phys-
ical activity could provide the solution to treat and
prevent obesity, in practice, the compliance in sus-
taining regular exercise is also poor, and there is
increased recognition of the need for alternative
or complementary strategies to enhance energy ex-
penditure (EE). In this context, there is consider-
able research interest in increasing thermogenesis
by targeting brown adipose tissue (BAT)—a richly
vascularized tissue whose primary function, under
sympathetic nervous system (SNS) activation, is to
produce heat through the uncoupling of oxidative
phosphorylation mediated by uncoupling protein 1
(UCP1), which is a mitochondrial protein that is
unique to these cells and hence distinguishes brown
adipocytes from white adipocytes and other cells.
The first era of BAT targeting
The concept of targeting BAT for obesity therapy
developed in the late 1970s, following a number of
classic studies in rodents suggesting that BAT is a
common effector site for sympathetically mediated
thermogenesis in response to both cold and diet,5–8
and that diminished sympathetic control of BAT
contributes importantly to defective thermogenesis
that underlies obesity, at least in part, in a variety of
genetic, hypothalamic, and dietary animal models.9
doi: 10.1111/nyas.12304
1Ann. N.Y. Acad. Sci. 1302 (2013) 1–10 C© 2013 The Authors Annals of the New York Academy of Sciences published by Wiley Periodicals, Inc.
on behalf of New York Academy of Sciences.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Translational issues in targeting brown fat Dulloo
The subsequent demonstration that bilateral sym-
pathetic denervation of interscapular BAT in lean
mice (housed at 25 ◦C) led to greater fat deposi-
tion owing to an elevated efficiency of energy uti-
lization (i.e., decreased thermogenesis)10 provided
more direct support of a role for BAT thermogenesis
pertaining to regulation of the body’s fat stores.
Despite skepticism about the relevance of these
findings for humans, in whom BAT was thought
to be absent beyond the neonatal period, enthusi-
asm for targeting BAT in obesity therapy persisted
throughout much of the 1980s. Indeed, anatom-
ical and histological studies11 have indicated the
widespread presence of BAT in adults who died af-
ter chronic exposure to cold or from patients with
pheochromocytoma (a catecholamine-releasing tu-
mor), thereby raising the possibility that even
though BAT undergoes involution after the neonatal
period, it could be reactivated or induced by chronic
adrenergic activation. The discovery in the 1980s
of atypical (3) adrenoceptors12 in BAT and white
adipose tissue (WAT) of rodents and subsequently
of humans, together with the findings that mice
treated chronically with 3 agonists13,14 showed the
presence of brown adipocytes within white fat de-
pots (now called browning of WAT) offered hope
for selective targeting in the development of ther-
mogenic drugs for the treatment of obesity.15 By the
late 1990s, however, enthusiasm had waned, largely
because the new drugs developed on the basis of
their selectivity for the 3 adrenoceptor in rodents
and that showed marked antiobesity efficacy in ro-
dents and dogs, had failed to fulfill the criteria of
a safe and effective therapy for human obesity15—a
situation that served to fuel further doubts about the
recruitability and functionality of BAT in the adult
human.
From pharmaceuticals to nutraceuticals
The difficulties of the pharmaceutical industry in
producing drugs with good efficacy, selectivity, and
pharmacokinetic properties suitable for stimulation
of the small number of 3 adrenoceptors present in
humans have created and sustained a vacuum in the
market for pharma-grade thermogenic products.
This vacuum has long been filled by the commer-
cialization of a plethora of herbal extracts and
nutraceutical products, whose pharmacologically
active ingredients—known for their actions at one
or more control points along the line of SNS control
(Fig. 1)—were shown to acutely increase thermoge-
nesis in humans and to promote fat losses associated
with increased BAT thermogenic capacity when
chronically administered to obese animal models.
Indeed, the thermogenic effects of ephedrine,
caffeine, catechin polyphenols, capsaicin-like com-
pounds, medium-chain triglycerides (substituting
long-chain triglycerides), and some specific polyun-
saturated fatty acids (e.g., linoleic acid, -linolenic
acids, docosahexanoic acid, and derivatives), have
been shown to be capable of stimulating UCP1
in BAT of rodents.16 The plausibility that these
bioactive herbal/food ingredients, via their sym-
pathomimetic properties, could be exerting part of
their thermogenic effects through (re)activation of
BAT in humans was (and still is) often underscored.
Several of these compounds have been tested as
pure grade compounds or as plant extracts in
humans during stays in whole-body calorimeter
chambers, and shown to increase 24-h EE by
values ranging from 4% to 8%;17–23 these data are
presented in Figure 2, together with those obtained
for cigarette smoking24 and alcohol intake.25
There is currently considerable impetus for the
nutraceutical and functional foods industry to cap-
italize on products that contain various combina-
tions of bioactive food ingredients, particularly in
light of evidence that in addition to their ther-
mogenic properties, they may also contribute to
negative fat balance through their effects in re-
ducing fat absorption (e.g., green tea polyphenols),
increasing spontaneous physical activity (e.g., caf-
feine), or in promoting satiety (caffeine, capsaicins,
and medium-chain-triglycerides).16 Overall, how-
ever, their effects on daily EE, in amounts or at doses
considered to be acceptable and safe, are very modest
(50–150 kcal/day). Although they may contribute
to weight control, the extra calories dissipated are
clearly far from any major clinical significance in the
treatment of obesity.
The second era of BAT targeting
During the past few years, the notion of targeting
BAT for enhancing thermogenesis in human obe-
sity therapy has been revitalized by a spate of land-
mark discoveries. First, the application of radiodi-
agnostic techniques (positron emission tomography
(PET)/computed tomography (CT)), coupled with
histology studies, to healthy humans have identi-
fied the presence of metabolically active BAT that
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Figure 1. Mechanisms by which bioactive food/herbal ingredients may modulate sympathetic control of thermogenesis. Sym-
pathetically mediated norepinephrine (NE) release and actions (via  adrenoceptors) are under negative-feedback modulation by
(1) adenosine, certain prostaglandins, and catechol-O-methyl transferase (COMT) in synaptic neuroeffector junction; and (2) at
the cellular level by phosphodiesterases, which break down NE-induced cyclic adenosine monophosphate (AMP). Thus, when NE
release is enhanced pharmacologically (e.g., by ephedrine) or by food ingestion, the inhibitory effects of adenosine, COMT, and
phosphodiesterases on further NE release and actions could be opposed by xanthines (e.g., caffeine), salicylates (e.g., aspirin), or
flavonoid polyphenols (e.g., green tea catechins). Thus, the stimulatory effect of NE on thermogenesis and fat oxidation could be
increased and/or prolonged. Adapted, with permission, from Dulloo.16
becomes apparent (mostly in the supraclavicular
and paravertebral regions) by relatively short expo-
sure to mild cold.26–30 Second, studies in genetically
engineered murine models have established that the
development of BAT thermogenic capacity for adap-
tive thermogenesis involves not only processes of re-
cruitment through hypertrophy and hyperplasia of
classic brown adipocytes in defined anatomical BAT
depots, but also by processes that induce the brown-
ing of WAT.31 The latter is defined as the appear-
ance of functional brown adipocytes in WAT after
chronic thermogenic stimulation and referred to as
brite (brown-in-white) or beige adipocytes. Third,
and what seems pivotal in the search for molec-
ular targets in activating BAT thermogenesis, are
the demonstrations that these two types of brown
adipocytes (classic vs. brite) may derive from dis-
tinct precursors and possess distinct molecular sig-
natures. Whereas the classic developmentally pro-
grammed brown adipocyte arises from mesenchy-
mal precursor cells common to the myogenic cell
lineage, the brite/beige adipocyte derives from pre-
cursor cells that are closer to the white adipocyte
cell lineage.32 Some have argued, however, that this
process of browning of WAT may also involve trans-
differentiation processes of white-to-brown adipose
cells.33,34 Whatever their developmental origins, the
observations that human BAT may derive predom-
inantly from the browning process and that the for-
mation of brite/beige adipocytes is induced not only
in response to SNS activation, but also to a vari-
ety of endocrine factors secreted by the liver (e.g.,
fibroblast growth factor 21), skeletal muscle (e.g.,
irisin) and heart (e.g., natriuretic peptides), have
highlighted the potential relevance of brite/beige
adipocytes in determining the total BAT thermo-
genic capacity in humans.35
There is considerable optimism that a better un-
derstanding of how these newly identified endocrine
factors, which control the signaling pathways that
activate classic BAT or induce browning of WAT
(or both), will pave the way for novel therapeutic
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Figure 2. Percent increase in 24-h energy expenditure, assessed in indirect calorimetry (respiration) chambers, in response to
drugs and other compounds and extracts screened for thermogenic properties (reviewed in detail in Ref. 16).
opportunities to stimulate BAT thermogenesis.
There are, however, a number of issues of central
importance that need to be considered when devel-
oping an ideal thermogenic antiobesity approach.
Several of these issues emerged during the first era
of BAT targeting and are now examined in light of
the current state of knowledge about the relative ef-
ficacy of various forms of obesity therapy, human
energy metabolism, and the biology of BAT.
How much of an increase in daily EE
should we aim for?
Independently of future approaches to re-
cruit or induce BAT thermogenesis, whether by
pharmacological,15 nutraceutical,16,36 or transplan-
tation therapy,37 an issue of cardinal importance
concerns the extent to which whole-body thermo-
genesis should be stimulated in order to achieve
clinically significant weight loss. It is clear that the
attribution of efficacy to any thermogenic approach
for weight loss therapy would require that this ap-
proach is successful in achieving long-term weight
loss. In this context, weight loss efficacy will cer-
tainly be measured against that of bariatric surgery,
which is the only treatment for obesity resulting
in an average of more than 15% long-term weight
loss documented over 10–15 years, namely in the
Swedish Obesity Subjects (SOS) trial.38 In absolute
terms, this efficacy of bariatric surgery amounts to
long-term weight loss of 20 kg on average. The ques-
tion arises as to how much daily EE would have to be
increased by an ideal thermogenic approach in order
to reach similar long-term weight loss? The answer
to this question is discussed below from an analysis
of the fall in EE (energy gap) that would arise fol-
lowing a 20-kg weight loss achieved by dieting in an
average obese individual.39
Energy gap for weight maintenance after
20-kg weight loss
From a purely thermodynamic standpoint, a loss
in body weight will entail obligatory reductions
in several compartments of daily EE, in particu-
lar (1) less energy would be required to sustain basal
metabolism, since resting metabolic rate (RMR)—
the major component of daily EE—is a function
of body mass and in particular lean body mass,
and the weight lost includes not only fat but also
lean body mass; (2) less energy would also be re-
quired for the amount of energy spent in performing
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physical activity since from a consideration of sim-
ple mechanics, it costs less energy to move a lower
body mass; and (3) less energy would be dissipated
as the thermic effect of food since less food is con-
sumed during dieting.
Furthermore, it has been shown that body weight
is a good predictor of total 24-h EE in sedentary
subjects:40 the more severe the obesity, the greater
the daily EE, not only because of the higher lean
body mass and basal metabolic rate, but also because
of an increase in the energy cost of weight-bearing
activities (e.g., standing, walking, and spontaneous
movement) as this cost is related to body weight.
Limitations in the accurate measurements
of body composition during weight changes
notwithstanding,41 the available evidence also
suggests that the composition of excess weight gain
in the obese seems to be within the same range as
the composition of weight loss induced by dieting,
namely 70–80% fat and 20–30% fat-free mass.42,43
It therefore follows that the slope of the linear
regression observed between body weight and
24-h EE (assessed cross-sectionally in sedentary
individuals using respiration chambers) provides a
crude estimate of the change in daily EE associated
with each kg change in body weight, namely
20 kcal/kg/day on average.40,44,45 On the basis of
these estimates, it can be calculated that a weight
loss of 20-kg body weight in an obese patient will
result in an obligatory average reduction of 400 kcal
in daily EE. Besides this obligatory or passive energy
economy, further reductions in daily EE can also
be expected as it has repeatedly been demonstrated
that the fall in EE is greater than predicted by
the loss of body mass, thereby underscoring the
operation of mechanisms that actively promote
energy conservation through adaptive suppression
of thermogenesis.
In a review about the clinical significance of adap-
tive thermogenesis during weight loss, Major et al.46
point to several weight reduction programs, includ-
ing those that incorporate both diet and exercise,
where values of 100–220 kcal/day on average could
be ascribed to adaptive thermogenesis in the fall
of sedentary EE assessed as postabsorptive RMR
and/or sleeping EE. Furthermore, such adaptive
suppression of thermogenesis could also operate to
spare energy in the nonresting compartment of daily
EE, as judged by 10–27% increases in the mechani-
cal efficiency of walking or cycling following weight
Figure 3. Schematic diagram illustrating long-term weight
losses, basedonthe resultsof theSwedishObesitySubjects (SOS)
bariatric surgery study.38 The broken line represents the control
patients. Shown is the energy gap for long-term maintenance,
subdivided into components that represent passive (obligatory)
and active (adaptive thermogenesis) components.
loss, all of which would contribute to a further re-
duction in energy needs. Our more recent analysis
of the literature indicates that the energy economy
due to adaptive thermogenesis in the fall in total
EE (resting + nonresting) would be in the range of
100–300 kcal/day.47 Overall, therefore, the addition
of the latter values for the adaptive fall in daily EE to
the obligatory reduction of 400 kcal/day following
a 20-kg weight loss in obesity therapy will entail an
energy gap amounting to 500–700 kcal/day (Fig. 3).
Consequently, any approach that relies primarily on
increasing thermogenesis for achieving similar lev-
els of long-term weight loss achieved by bariatric
surgery will have to be effective in stimulating daily
EE by approximately 600 kcal daily, assuming no
change in energy intake. This is far above any in-
crease in 24-h EE documented so far in the search
for thermogenic compounds, which at safe doses
were found to be less than 150 kcal/day. The critical
question at this point is whether the adult human
body possesses such a capacity for thermogenesis
that could be exploited by future therapy.
Human capacity for nonshivering
thermogenesis
Adult humans clearly have the capacity to mount
substantial increases in nonshivering thermogene-
sis (NST) when acclimatized to cold. In the most
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recent cold-acclimation study,48 young adults were
wrapped in a water-perfused suit and exposed to
temperatures of 15–16 ◦C for 6 h daily for 10 consec-
utive days. The acute cold-induced NST expressed as
a percent of resting EE was shown to increase from
11% before cold acclimation to 18% at the end of
the 10 days of cold exposure (i.e., NST amounted to
175 kcal/day before and 290 kcal/day after 10 days of
cold acclimation). A much greater capacity for NST
was observed in the classic cold chamber experiment
of Davis,49 conducted in young subjects wearing
only shorts when acclimatized to a colder environ-
ment (12 ◦C) and for longer duration (8 h/day for
31 days). Indeed, after the first week of cold accli-
mation, during which shivering activity was found
to decline rapidly, the cold-induced elevation in
metabolic rate was sustained throughout the one-
month study, thereby implicating the recruitment
of large increases in NST for thermal regulation to
explain the 34% increase in metabolic rate. Trans-
lated to daily EE, such an increase in metabolic rate
would amount to a capacity for NST that exceeds
600 kcal/day. On the basis of this analysis, the case
can be put forward that adult humans have the ca-
pacity to increase thermogenesis to meet the goal of
the ideal thermogenic strategy for achieving long-
term weight loss of some 20 kilograms. How much of
this thermogenic capacity can be achieved through
BAT heat production per se and how much BAT
mass would be required to reach this level of thermo-
genic capacity are issues that are addressed below.
Quantitative contribution of BAT to
whole-body thermogenesis
From the recent study of cold acclimation men-
tioned above,48 the findings from PET/CT scanning
that BAT activity (assessed by fluorodeoxyglucose
(FDG) radiotracer uptake)) increased in parallel
with the increase in NST following cold acclimation
is certainly consistent with an important role for
BAT recruitment in NST in adult humans after
repeated intermittent cold exposures. Evidence
for consistency through associations, however, is
not evidence for causality. Nonetheless, those who
advocate a quantitatively important contribution of
BAT thermogenesis to cold-induced NST point to
the calculations of Rothwell and Stock,50 which are
based on data about the high metabolic rate of this
tissue in response to norepinephrine in hyperphagic
rats exhibiting diet-induced thermogenesis (1.7 mL
O2/g/min). On the basis of these calculations, they
have proposed that the activation of 40–50 g of ac-
tive BAT by norepinephrine in an average sedentary
man spending 2500 kcal/day would indeed corre-
spond to an increase of about 20% in daily EE. Thus,
an apparently trivial amount of BAT, if activated,
could have a profound influence on energy balance,
since 10–20% of daily EE (i.e., 250–500 kcal/day)
can make the difference between maintaining body
weight or gaining 10–20 kg within a few years.
There are, however, several counterarguments to
these calculations. In a revisit of these rat-to-human
data extrapolations, van Marken Lichtenbelt and
Schrauwen51 have questioned these estimates on
the basis of the allometric differences between small
rodents and humans, while also underscoring that
maximal BAT stimulation is unlikely to be reached
under physiological conditions. They argue that
50 g of active BAT in humans could contribute to
only 3–5% of basal metabolic rate. These values are
in accord with the conclusions reached by Virtanen
et al.28 using glucose-uptake estimates made dur-
ing PET/CT scanning in a study where BAT activity
was found to contribute to 4.5% of BMR in subjects
acutely exposed to cold. An even lower contribution
of BAT thermogenesis to the whole-body EE in re-
sponse to acute cold exposure (16 ◦C) in humans
has been reported by Muzik et al.52 who used dy-
namic oxygen-15 PET imaging to study oxidative
metabolism in BAT depots based on independent
measurements of both blood flow and oxygen ex-
traction. BAT thermogenesis was found to account
for less than 2% of the increase in whole-body EE
(i.e., less than 20 kcal/day) even in subjects showing
relatively large BAT activity (assessed by FDG tracer
uptake) and large increases in whole-body EE of ap-
proximately 300 kcal/day on average. According to
these authors,52 these results beg the questions of
whether the glucose that is transported in human
BAT during cold exposure is stored, oxidized, or
released as lactate, and whether the elevated FDG
uptake in BAT is an epiphenomenon. Furthermore,
because of large differences in blood flow and glu-
cose oxidation in BAT between humans and rodents,
the extrapolation of rodent data to humans may lead
to erroneous conclusions.
How much BAT do humans possess?
Estimates of the mass of BAT vary considerably
across studies, with some reports showing that
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values for the total volume of BAT amount to less
than 50 g in most individuals, while others reporting
values in the range of up to 100–200 grams.28 The
figure depends critically on the type and intensity
of prior cold exposure and on the definition crite-
ria for the positive BAT FDG uptake. Furthermore,
it should be emphasized that human BAT depots
contain a mixture of brown adipocytes interspersed
within a greater volume of white adipocytes that
have much lower metabolic activity. Although mea-
sures of BAT by FDG uptake and PET/CT have so far
been considered the gold standard, this technique is
limited by poor reproducibility and insufficient res-
olution to localize microscopic patches of brown
adipocytes. As emphasized by Muzik et al.,52 PET
imaging provides an average metabolic activity of a
mixed cell population within the anatomically de-
fined depot, such that the low average activity of
human BAT depots may reflect the relatively low
density of brown adipocytes. Indeed, the presence
of UCP1 in supraclavicular adipose tissue has been
revealed even when the results of PET/CT scans are
negative53 (most likely due to suboptimal sensitivity
of standard PET/CT), thereby reinforcing the con-
tention that the prevalence of BAT is higher than so
far recognized in adult humans, and the potential
for its recruitment and induction by future thermo-
genic therapies remains plausible. But whether such
recruitment/induction will translate into a major
contribution to the level of whole-body thermoge-
nesis required for clinically significant therapeutic
weight loss will have to await further development
of more refined tools for human BAT detection and
functional state assessment.
UCP1-independent nonshivering
thermogenesis
It should be emphasized that UCP1-independent
thermogenic mechanisms and other organs and
tissues can also be recruited for NST. When housed
at low temperatures (20 ◦C) and fed a high-fat diet,
mice deficient in UCP1 are more resistant to obesity
than wild-type controls without consuming less
food,54 thereby underscoring the recruitment of
alternative thermogenic mechanisms, which could
be associated with increased oxidative capacity
in WAT.55 One should also recall the studies of
blood flow coupled with regional arteriovenous
oxygen differences conducted by Foster and
colleagues in the 1980s,56,57 which indicated that
interscapular BAT oxygen consumption, although
increased markedly by cold exposure, was not in-
duced in rats exhibiting diet-induced thermogenesis
in response to cafeteria overfeeding.56 Subsequent
studies underscored a quantitatively important
role for the liver in the mediation of the adaptive
increase in thermogenesis in response to caloric
excess.57
Cardiac responses to stimulation of
thermogenesis
A concern that is often raised about strategies to
manage obesity by targeting thermogenesis is that
it will result in an increased heart rate. Indeed,
as EE increases, the work done by the heart must
also increase to meet the body’s greater demand
for oxygen. During exercise, there is a fairly close
relationship between heart rate and EE, to the ex-
tent that the field technique for continuously mea-
suring heart rate has been used to estimate EE
in humans. However, the relationship between EE
and heart rate is curvilinear, and at low levels of
increased EE (less than twofold), heart rate does
not increase as steeply for a given change in EE,
probably due to changes in stroke volume. Con-
sequently, an increase in heart rate in response to
an extra demand in oxygen resulting from a 25%
increase in daily EE is likely to be marginal. To
put this into context, simply chewing gum (8.4 g,
energy-free) increases EE by approximately 20%,58
and in our laboratory, intermittent leg-press exer-
cise of low intensity (while comfortably seated) in-
creased EE by 65%, with heart rate increasing by only
5–7 beats/min.59
Impact of increased thermogenesis on
appetite
It has long been known, from studies conducted
both in humans and in animal models, that two
of the most potent stimuli of heat production—
the thyroid hormones and exercise—increase food
intake, and the case is often put forward that fu-
ture thermogenic strategies could also be limited
by compensatory increases in food intake. How-
ever, the view that targeting thermogenesis will al-
most inevitably lead to a compensatory increase in
food intake is not supported by the data gathered
over the past decades in the search for thermo-
genic stimulants. Neither the numerous 3 adreno-
ceptor agonists that have been screened,15 nor the
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administration of the bioactive food ingredients
with thermogenic properties,16 led to increased food
intake in obese animals; if anything, energy intake
tended to be lower in some cases.
Conclusions
On the basis of the analysis of human data on the
activation of NST during cold acclimation, humans
have the potential to increase their whole-body ther-
mogenic capacity to achieve long-term weight loss
currently achievable only through bariatric surgery.
The quantitative contribution of BAT to this ther-
mogenic capacity is at present uncertain, but judg-
ing from the anatomic and histological data of adult
humans who died from chronic cold exposure or
from some patients with pheochromocytoma, the
recruitability/induction of BAT can be impressive
under chronic stimulation. With the current surge
in research focused on unraveling the biology of
BAT, and with likely advances in human BAT de-
tection and activity assessment by PET/CT technol-
ogy coupled to magnetic resonance imaging (MRI)
techniques, there is no doubt that new therapeutic
avenues for research will continue to develop to-
ward enhancing thermogenesis by BAT targeting.
The enthusiasm to move along these research av-
enues is further driven by the notion that even if
the weight loss efficacy of these future therapeutic
approaches prove to be modest, the role of BAT as
a sink for glucose and lipid utilization may prove
to be efficacious for the long-term management of
type 2 diabetes and other obesity-associated comor-
bidities. Amidst such excitement and optimism that
this second era of BAT targeting would materialize
into the development of effective and safe thermo-
genic antiobesity and/or antidiabetic therapies, a
few words of caution might seem somewhat mis-
placed. But as recent history in the field of obesity
has taught us, whether when dealing with transgenic
mice in assessing the role of UCP1, UCP2, or UCP3
in weight homeostasis; when translating promising
research findings from rodents and dogs to humans
(the 3 agonist failures); or when “successful” clin-
ical trials translate into therapeutic fiascos (such as
that associated with rimonabant); we need to be pre-
pared to expect the unexpected and hope that our
motivation to put “fat in the fire” does not backfire
on the century-old concept of treating obesity by
stimulating thermogenesis.
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